PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 30, 2024JAMA80 citations

Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery

View Full Paper
MLMatthieu LegrandJFJérémy FalconeBCBernard Cholley

Key Points

Key points are not available for this paper at this time.

Abstract

Before surgery, the best strategy for managing patients who are taking renin-angiotensin system inhibitors (RASIs) (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) is unknown. The lack of evidence leads to conflicting guidelines.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Legrand et al. (2024) studied this question.

synapsesocial.com/papers/68e5a2bab6db64358753cfe7https://doi.org/10.1001/jama.2024.17123
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 12014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management2014 · 1,677 citations
  2. 2Discontinuation vs. continuation of renin–angiotensin system inhibition before non-cardiac surgery: the SPACE trial2023 · 64 citations
  3. 32014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery2014 · 1,823 citations
  4. 4Impact of renin-angiotensin system inhibitors continuation versus discontinuation on outcome after major surgery: protocol of a multicenter randomized, controlled trial (STOP-or-NOT trial)2019 · 36 citations
  5. 5Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery2023 · 168 citations